Acumen Pharmaceuticals (ABOS) Competitors $1.16 +0.04 (+3.10%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. RCKT, AVTE, GLUE, PRME, OLMA, AVIR, ADCT, TRDA, CRVS, and ALLOShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Rocket Pharmaceuticals (RCKT), Aerovate Therapeutics (AVTE), Monte Rosa Therapeutics (GLUE), Prime Medicine (PRME), Olema Pharmaceuticals (OLMA), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Entrada Therapeutics (TRDA), Corvus Pharmaceuticals (CRVS), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Its Competitors Rocket Pharmaceuticals Aerovate Therapeutics Monte Rosa Therapeutics Prime Medicine Olema Pharmaceuticals Atea Pharmaceuticals ADC Therapeutics Entrada Therapeutics Corvus Pharmaceuticals Allogene Therapeutics Rocket Pharmaceuticals (NASDAQ:RCKT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends. Which has more risk & volatility, RCKT or ABOS? Rocket Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Which has higher valuation & earnings, RCKT or ABOS? Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$258.75M-$2.63-1.10Acumen PharmaceuticalsN/AN/A-$102.33M-$1.94-0.60 Do institutionals and insiders have more ownership in RCKT or ABOS? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer RCKT or ABOS? In the previous week, Rocket Pharmaceuticals had 50 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 51 mentions for Rocket Pharmaceuticals and 1 mentions for Acumen Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.02 beat Acumen Pharmaceuticals' score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 40 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RCKT or ABOS more profitable? Acumen Pharmaceuticals' return on equity of -58.24% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -64.92% -56.13% Acumen Pharmaceuticals N/A -58.24%-46.53% Do analysts recommend RCKT or ABOS? Rocket Pharmaceuticals presently has a consensus price target of $18.60, indicating a potential upside of 542.27%. Acumen Pharmaceuticals has a consensus price target of $6.33, indicating a potential upside of 443.63%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryRocket Pharmaceuticals beats Acumen Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.45M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.6021.4227.3820.03Price / SalesN/A281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book0.387.518.085.67Net Income-$102.33M-$55.05M$3.16B$248.47M7 Day Performance-3.72%3.16%2.12%2.90%1 Month Performance12.02%5.92%4.43%5.75%1 Year Performance-50.84%5.82%35.62%21.36% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals1.3188 of 5 stars$1.17+3.1%$6.33+443.6%-50.2%$68.45MN/A-0.6020News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8856 of 5 stars$2.63-2.6%$18.60+607.2%-85.4%$288.32MN/A-1.00240Trending NewsAVTEAerovate TherapeuticsN/A$9.89+5.1%N/A-82.4%$286.66MN/A-3.3120High Trading VolumeGLUEMonte Rosa Therapeutics1.1827 of 5 stars$4.64+0.2%$15.50+234.1%+31.8%$284.79M$75.62M58.0190News CoveragePRMEPrime Medicine3.5774 of 5 stars$2.16+4.3%$10.08+366.8%-41.9%$283.60M$3.85M-1.05234Gap UpHigh Trading VolumeOLMAOlema Pharmaceuticals1.7527 of 5 stars$4.19+1.5%$24.50+484.7%-56.4%$282.58MN/A-2.0870News CoverageAVIRAtea Pharmaceuticals2.377 of 5 stars$3.32+2.2%$6.00+80.7%+12.4%$278.13MN/A-2.0170News CoverageADCTADC Therapeutics1.7122 of 5 stars$2.68-3.2%$7.75+189.2%-19.0%$274.72M$70.84M-1.85310TRDAEntrada Therapeutics3.3656 of 5 stars$7.04-1.1%$25.67+264.6%-48.1%$270.23M$210.78M8.69110Insider TradeCRVSCorvus Pharmaceuticals2.503 of 5 stars$3.73-5.8%$15.00+302.1%+123.6%$269.95MN/A-3.8130Insider TradeALLOAllogene Therapeutics3.0264 of 5 stars$1.22-0.8%$8.44+592.2%-44.4%$269.04M$20K-0.99310 Related Companies and Tools Related Companies RCKT Competitors AVTE Competitors GLUE Competitors PRME Competitors OLMA Competitors AVIR Competitors ADCT Competitors TRDA Competitors CRVS Competitors ALLO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
